Article
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
JAMA oncology - 1 Jun 2017
Connor Ashton A, Denroche Robert E, Jang Gun Ho, Timms Lee, Kalimuthu Sangeetha N, Selander Iris, McPherson Treasa, Wilson Gavin W, Chan-Seng-Yue Michelle A, Borozan Ivan, Ferretti Vincent, Grant Robert C, Lungu Ilinca M, Costello Eithne, Greenhalf William, Palmer Daniel, Ghaneh Paula, Neoptolemos John P, Buchler Markus, Petersen Gloria, Thayer Sarah, Hollingsworth Michael A, Sherker Alana, Durocher Daniel, Dhani Neesha, Hedley David, Serra Stefano, Pollett Aaron, Roehrl Michael H A, Bavi Prashant, Bartlett John M S, Cleary Sean, Wilson Julie M, Alexandrov Ludmil B, Moore Malcolm, Wouters Bradly G, McPherson John D, Notta Faiyaz, Stein Lincoln D, Gallinger Steven
Abstract excerpt
IMPORTANCE: Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. Advances in next-generation sequencing provide a route to therapeutic approaches, and integrating DNA and RNA analysis with clinicopathologic data may be a crucial step toward personalized treatment strategies for this disease. OBJECTIVE: To classify PDAC according to distinct mutational processes, and explore their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
